Background {#Sec1}
==========

Cancer of the uterine cervix represents the fourth most common malignancy among females and accounts for 7.5% of all cancer deaths in women worldwide. Due to lack of systemic screening programs, developing countries share the 85% of the global burden, with cervical cancer accounting for 12% of all cancers among women in these countries \[[@CR1]\]. Patients with metastatic or recurrent cervical cancer are treated mainly with palliative chemotherapy. In this setting, cisplatin may be combined with either paclitaxel, topotecan, gemcitabine or vinorelbine, since no significant differences in OS (overall survival) have been observed between these regimens, although survival trends and toxicity profiles seem to favor the cisplatin and paclitaxel combination \[[@CR2], [@CR3]\]. Lately, significant therapeutic progress has been documented by adding the antiangiogenic agent bevacizumab to the standard cisplatin-paclitaxel or topotecan-paclitaxel regiments, that extended median OS from 13.3 to 17 months, as shown in the GOG 204 trial \[[@CR4]\]. However, one should keep in mind that this gain comes with a significant incremental cost-effectiveness ratio (ICER) that is over \$120,000/quality adjusted life year (QALY), almost double than the willingness-to-pay (WT) of \$50,000--\$62,500/QALY in the US, according to recent cost-effectiveness studies \[[@CR5]\].

Resistance to chemotherapy is widely recognized as one of the major factors that limit therapeutic efficacy and influence patient outcomes. Cisplatin and carboplatin are alkylating compounds that exert their cytotoxic action by binding to DNA and forming strong inter- and intra-structural cross links, thus inhibiting DNA replication \[[@CR6]\]. Excision repair cross-complement 1 (*ERCC1*) is a 15-kb human nucleotide excision repair gene with already documented importance in developing resistance to platinum compounds in NSCLC (non small cell lung cancer), ovarian, colorectal and cervical cancer \[[@CR7]--[@CR11]\]. Most of the ERCC1 genes studied are polymorphic. These SNPs may or not alter the protein function. Even if they do not result in an amino acid change they may cause mRNA instability and increase the risk of environmentally induced cancer \[[@CR12]\].

Class III tubulin is a common target for taxane chemotherapy and its overexpression has been associated with resistance in patients with NSCLC, breast cancer and gastric cancer treated with tubulin binding agents \[[@CR13]\]. The Multiple Drug Resistance 1 (*MDR-1*) gene is a highly polymorphic gene that codes for the membrane transporter P-glycoprotein and its variations have been associated with influenced protein function, altered kinetics of anticancer drugs and respective patient outcomes \[[@CR14]--[@CR16]\]. Moreover, it has been described that cyclooxygenase 2 (COX-2) plays a role in carcinogenesis of cervical, ovarian and endometrial neoplasms by inhibiting surveillance by the immune system, neo-angiogenesis and apoptosis \[[@CR17]--[@CR19]\]. Efficient immune response requires activation of CD4 and CD8 T lymphocytes and activation of tumor-infiltrating cytotoxic T lymphocytes is correlated with improved survival in cervical, endometrial, ovarian, pancreatic and colorectal cancers \[[@CR20]--[@CR24]\].

The above markers were chosen based on their previous correlation with survival in locally advanced cervical cancer (LACC) and other cancer subtypes, as well as on previous references associating them with platinum or taxane resistance. We did not attempt to make a gene signature. The aim of this study was to confirm or not the prognostic and or predictive value of these specific markers in the metastatic and or recurrent cervical cancer setting. Specifically we tested whether ERCC1 expression and two frequently described SNPs (single nucleotide polymorphisms) *ERCC1* (C8092A and N118 N) could predict response and clinical outcomes in metastatic or recurrent cervical cancer patients treated with cisplatin-based chemotherapy. We also evaluated if there are any associations between the two common polymorphisms in *MDR1* gene (C3435T and G2677 T), as well as class III β-tubulin with survival and chemotherapy resistance in the same population. Finally, we looked for possible correlations between tumor microenvironment expression of COX-2, and percentage of CD4 and CD8 tumor infiltrating lymphocytes (TILs) with patient characteristics and clinical outcomes.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

Tissue samples from patients that participated in a randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel were provided for retrograde analysis. This trial randomly allocated one hundred and fifty-three patients to receive either ifosfamide 1.5 g/m^2^, daily, on days 1--3 and cisplatin 70 mg/m^2^ on day 2 (IP regimen) or the same combination with the addition of paclitaxel 175 mg/m^2^, on day 1 (ITP regimen), every 4 weeks \[[@CR25]\]. Retrograde immunohistochemical analysis and genotyping was performed to eventually 45 available tissue samples, as well as correlation with patient characteristics and outcomes. World Health Organization criteria for response were used \[[@CR26]\]. Eligible patients had primary metastatic or recurrent carcinoma of the uterine cervix, not amenable to surgery and/or radiation therapy and had not been treated with prior chemotherapy except for cisplatin chemo-radiation.

Immunohistochemistry {#Sec4}
--------------------

Tissue samples were removed and embedded in 10% neutral--buffered formalin. Sections were then dehydrated in graded series of ethanol concentrations of 50%, 60%, 70%, 80%, 90% and 100%, respectively. The tissue intubation time in each ethanol solution was 90 min. Subsequently, the tissue was embedded in 2 xylene and 3 alcohol buffers for 90 min each. The whole procedure lasted 18 h.

Tissue fixation followed in paraffin blocks and sections of 4 μm were cut and placed on specific ionized slides (SuperFrost™ Plus) in order to avoid their autoagglutination. Immunohistochemistry was performed on an automated immunohistochemistry system (Bond-Max, Leica). The required dewax and antigen retrieval procedures were both automated and performed by the use of Bond Dewax Solution and Bond Epitope Retrieval Solution 1 and 2 (Leica Biosystems), respectively. For antibody labeling the Bond Polymer Refine Red Detection Kit (Leica Biosystems) was used. Staining was achieved through the Fast Red Chromogen System (BioLegend), and counterstaining through a 0.02% haematoxylin solution. Finally, tissue dehydration in graded alcohol and xylene was done and microscopic examination was performed. The following monoclonal antibodies were used: For ΕRCC1, IgG2b, clone 8F1(1:70) and for COX-2, IgG1, clone 4H12, (1:30) (both Diagnostic BioSystems Inc., Pleasanton, CA, USA). For III β-tubulin, IgG1, clone OTI5H2 (1:70) (Acris Antibodies Inc., San Diego, CA, USA). For CD4, IgG1 antibody, clone 4B12, (1:80) and for CD8, IgG1, clone 1A5, (1:20) (both Novocastra Inc.).

Staining evaluation {#Sec5}
-------------------

Two independent pathologists who were blinded for patient's identity, characteristics and outcomes performed the immunochemistry assessment. Positive reaction was expressed based on the percentage of tumor cells with membrane staining (0: 0%; 1: 0--10%; 2: 10--50%; 3: \>50% of stained tumor cells). We considered as positive the samples with over 50% of tumors cells stained. A third pathologist reviewed discordant cases.

Genotyping {#Sec6}
----------

Genotyping of *ERCC1* C8092A and N118 N were determined by using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay as previously described \[[@CR27], [@CR28]\]. The primers used were: For the C8092A, 8092F: 5′-ACCCCACTCTAGATTTACCCAGGAA-3′ and 8092R: 5′-AAGAAGCAGAGTCAGGAAAGC-3′. The PCR products were digested with the restriction enzyme MboII. For the N118 N polymorphism 118F: 5′-AGGACCACAGGACACGCAGA-3′ and 118R: 5′-CATAGAACAGTCCAGAAC AC-3′, respectively. The PCR products were digested with restriction enzyme BsrdI to determine the genotypes.

Genotyping of *MDR1* C3435T (exon 26) and G2677 T (exon 21) were also determined by using the PCR-RFLP assay as previously described \[[@CR29], [@CR30]\]. Specifically, PCR amplifications were carried out in a total volume of 50 μl containing: 100 ng of genomic DNA, 1 U of Taq Polymerase (MBI Fermentas), 1 μM of each primer (for C3435T, F: 5′-TTG ATG GCA AAG AAA TAA AGC-3′ and R: 5′-CTT ACA TTA GGC AGT GAC TCG-3′; for G2677 T, F: 5′-TTT GCA GGC TAT AGG TTC CAG-3′, and R(T): 5′-TTT AGT TTG ACT CAC CTT CCC G-3′), 1XPCR buffer, 1 mM MgCl~2~, and 0.04 mM dNTPs. The PCR products were digested by restriction endonucleases MboI (for C3435T) and BanI (for G2677 T).

Statistical analysis {#Sec7}
--------------------

Chi-square test and Fisher's exact test were used for comparisons between groups with categorical variables. Multivariate analysis for predictors of categorical dichotomous outcomes was performed with logistic regression. Overall and progression-free survivals (PFS) were estimated with the Kaplan-Meier method, which was also used for comparisons of survivals among different groups. Multivariate survival analysis was performed with Cox regression with the forward conditional method. All tests were two-tailed. The results were considered statistically significant if *p* \< 0.05.

Results {#Sec8}
=======

Demographics {#Sec9}
------------

Main patients' characteristics are summarized in Table [1](#Tab1){ref-type="table"}. The median patient age was 58 years (range 32--76). Squamous cell carcinoma accounted for 72.1% (*n* = 31), followed by adenocarcinoma (*n* = 6, 14%), and mixed histological types (*n* = 6, 14%). Of the total 43 patients, 22 received the ITP regimen and 21 the IP regimen. 42 out of the 43 patients (97.7%) showed disease progression during the surveillance period and thirty-seven out of the 43 patients (86%) died. The median PFS of the patients in our cohort was 6 months (range: 0.2--57.3 months) and the median OS was 11.6 months (range: 0.2--81 months). Data on immunohistochemistry expression of the tested proteins and selected single nucleotide polymorphisms of this metastatic or recurrent cervical cancer cohort is summarized in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} respectively.Table 1Selected patient characteristicsCharacteristicNo of patients (%)*p*-valueITPIPTotal patients2221Age (years) Median58580.646 Range32--7835--75Histology Squamous13 (59.1)18 (85.7)0.129 Adenocarcinoma4 (18.2)2 (9.5) Mixed5 (22.7)1 (4.8)Overall response CR5 (22.7)1 (4.8)0.038 PR10 (45.5)4 (19) SD2 (9.1)5 (23.8) PD5 (22.7)11 (52.4)*ITP* Ifosfamide Paclitaxel Cisplatin, *IP* Ifosfamide Cisplatin, *CR* Complete Response, *PR* Partial Response, *SD* Stable Disease, *PD* Progressive Disease Table 2Immunohistochemistry patient dataProtein ExpressionNo of patients (%)*p*-valueITPIPERCC 1 High11 (50)9 (42.9)0.906 Moderate5 (22.7)7 (33.3) Low2 (9.1)2 (9.5) None4 (18.2)3 (14.3)COX 2 High7 (31.8)5 (23.8)0.342 Moderate5 (22.7)7 (33.3) Low4 (18.2)7 (33.3) None6 (27.3)2 (9.5)III beta tubulin High11 (50)9 (42.9)0.425 Moderate8 (36.4)5 (23.8) Low3 (13.6)6 (28.6) None0 (0)1 (4.8)CD4 High0 (0)0 (0)0.768 Moderate3 (13.6)4 (19) Low6 (27.3)7 (33.3) None13 (59.1)10 (47.6)CD8 High1(4.5)0 (0)0.226 Moderate3 (13.6)3 (14.3) Low3 (13.6)8 (38.1) None15 (68.2)10 (47.6)*ITP* Ifosfamide Paclitaxel Cisplatin, *IP* Ifosfamide Cisplatin Table 3Selected single nucleotide polymorphisms patient dataSNPsNo of patients (%)*p*-valueITPIP*MDR1* C3435TPolymorphisms CT13 (59.1)14 (66.6)1 CC4 (18.2)3 (14.3) TT5 (22.7)4 (19)*MDR1* G2677 TPolymorphisms GT5 (22.7)5 (23.8)0.904 GG15 (68.2)13 (61.9) TT2 (9.1)3 (14.3)*ERCC1* C8092APolymorphisms CA9 (40.9)8 (38.1)1 CC11 (50)10 (47.6) AA2 (9.1))3 (14.3)*ERCC1* N118 NPolymorphisms CT8 (36.4)12 (57.1)0.371 CC3 (13.6)3(14.3) TT11 (50)6 (28.6)*ITP* Ifosfamide Paclitaxel Cisplatin, *IP* Ifosfamide Cisplatin

Protein expression association with patient characteristics {#Sec10}
-----------------------------------------------------------

Histological type of cervical cancer seemed to be associated with COX2 and CD8 protein expression. COX2 was expressed in the great majority of squamous carcinomas (90.3%) and in 66.7% and 50% of adenosquamous and adenocarcinomas respectively (*p* = 0.034). Although of marginal statistical significance (*p* = 0.05), CD8 was also more abundantly expressed in squamous carcinomas (51.6%) than in adenocarcinomas (33.3%) and adenosquamous carcinomas (0%). No significant associations were found between age and the expression of ERCC1 (*p* = 0.706), COX2 (*p* = 0.731), tubulin B3 (*p* = 0.529), CD4 (*p* = 0.515) or CD8 (*p* = 0.281) TILs.

Genotype distributions and their association with patient characteristics and protein expression {#Sec11}
------------------------------------------------------------------------------------------------

Similarly, no significant associations were found between age or histological type the presence of the following polymorphisms: *MDR1* C3435T (*p* = 0.253), *MDR1* G2677 T (*p* = 0.609), *ERCC1* C8092A (*p* = 1), *ERCC1* N118 N (*p* = 0.684). On the contrary, the polymorphism *ERCC1* N118 N seemed to influence the production of ERCC1, since all the tumors with CT genotype were stained positive for ERCC1 protein \[20/20 (100%)\], whereas this was not the case for the other two tested alternatives \[CC: 4/6 (66.6%), TT: 12/17 (70.6%)\] (*p* = 0.013).

Immunohistochemisrty associations with response and survival outcomes {#Sec12}
---------------------------------------------------------------------

As it has been previously published, patients on the ITP regimen demonstrated significantly higher response to chemotherapy and improved survival outcomes \[[@CR25]\]. In our study, no significant correlations were observed between the response rates and the levels of ERCC1 expression (*p* = 0.13). Responses were influenced by the expression of some of the other examined proteins. Specifically, patients with high ΙΙΙ β-tubulin expression demonstrated decreased complete or partial responses \[5/20 (25%)\] compared to patients with lower or no expression of ΙΙΙ β-tubulin \[15/23 (65.2%)\] (*p* = 0.008). The type of chemotherapy regimen and the levels of ΙΙΙ β-tubulin remained independent predictors of response to the treatment after multivariate analysis using logistic regression. In particular, patients having received the ITP regimen had more objective responses than patients having received the IP regimen \[HR = 22.45 (95% CI: 2.486--202.725), *p* = 0.006,\] and patients with high ΙΙΙ β-tubulin expression had less objective responses than patients with lower or no ΙΙΙ β-tubulin expression \[HR = 0.52 (95% CI: 0.006--0.469) *p* = 0.008\]. Five out of eleven patients (45.5%) in the ITP regimen and five out of twelve (541.7%) patients in the IP regimen had progressing disease (PD) when ΙΙΙ β-tubulin was overexpressed compared to 0% of patients progressing in either treatment arms when lower or absent III β-tubulin was expressed (*p* = 0.035 and *p* = 0.045 for the ITP and IP respectively).

PFS and OS according to the tested parameters are summarized in Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, for the ITP + IP, ITP and IP groups respectively. III β-tubulin expression did not significantly affect OS or PFS in either ITP or IP group. However, ERCC1 expression showed a strong negative correlation with PFS and OS in this metastatic cervical cancer cohort. Median OS for patients with high or moderate levels of ERCC1 was 10.5 months versus 21.4 months for patients with low or no ERCC1 production (*p* = 0.006) (Fig. [1](#Fig1){ref-type="fig"}). Median PFS was also significantly shorter in patients with ERCC1 overexpression (mPFS: 5.1 months vs 10.2 months respectively, *p* = 0.027) (Fig. [2](#Fig2){ref-type="fig"}). When we conducted multivariate survival analysis using Cox regression, only ERCC1 expression remained an independent predictor of both the OS \[HR = 3.187 (95% CI: 1.346--7.546), *p* = 0.008,\] and the PFS \[HR = 2.473 (95% CI: 1.146--5.339), *p* = 0.021\].Table 4OS and PFS (all patients)Median OS (months)Median PFS (months)Protein ExpressionLowHigh*P*-valueLowHigh*P*-value ERCC121.410.50.00610.25.10.027 COX217.710.50.0516.55.20.463 Tubulin B311.611.90.704660.347 CD411.911.90.4465.68.80.253 CD813.58.60.04163.90.766SNPs  *MDR1* C3435TCCTTCT*P*-valueCCTTCT*P*-value20.216.510.50.197.96.660.654  *MDR1 G2677 T*GGTTGTGGTTGT8.63.617.70.1195.12.98.60.027  *ERCC1C8092A*AACCCAAACCCA25.211.615.40.7562.8660.543  *ERCC1 N118 N*CCTTCTCCTTCT8.221.48.50.0635.28.83.90.006 Table 5OS and PFS (ITP group)Median OS (months)Median PFS (months)Protein ExpressionLowHigh*P*-valueLowHigh*P*-value ERCC121.410.50.0498.260.558 COX217.710.50.3637.960.895 Tubulin B311.916.40.5298.27.90.74 CD411.925.50.3976.610.10.113 CD811.95.40.4767.91.20.707SNPs MDR1 C3435TCCTTCT*P*-valueCCTTCT*P*-value3.411.911.70.4671.88.88.10.484 MDR1 G2677 TGGTTGTGGTTGT11.92.921.90.6476.52.98.60.494 ERCC1C8092AAACCCAAACCCA25.211.911.90.66410.27.96.50.702 ERCC1 N118 NCCTTCTCCTTCT11.621.65.60.4018.210.13.60.003 Table 6OS and PFS (IP group)Median OS (months)Median PFS (months)Protein ExpressionLowHigh*P*-valueLowHigh*P*-value ERCC120.28.60.11420.23.90.045 COX215.48.60.1065.12.90.362 Tubulin B35.410.60.3494.93.90.419 CD48.63.60.9464.92.80.81 CD88.615.40.9194.93.90.924SNPs MDR1 C3435TCCTTCT*P*-valueCCTTCT*P*-value13.515.48.20.3188.54.92.80.374 MDR1 G2677 TGGTTGTGGTTGT8.23.615.40.1043.92.8120.041 ERCC1C8092AAACCCAAACCCA3.68.615.40.140.93.95.10.008 ERCC1 N118 NCCTTCTCCTTCT8.210.68.50.3945.16.43.90.195 Fig. 1OS according to ERCC1 expression. Patients with moderate or high levels of ERCC1 had shorter overall survival \[median OS: 10.5 months mean OS ± SE: 12.5 months ±1.9 (95% CI: 8.8--16.3),\] than patients with low or no ERCC1 production \[median OS: 21.4 months, mean OS ± SE: 37.9 months ±10 (95% CI: 18.3--57.5)\] (*p* = 0.006). OS, Overall Survival Fig. 2PFS according to ERCC1 expression. Patients with moderate or high levels of ERCC1 had shorter progression-free survival \[median PFS: 5.1 months, mean PFS ± SE: 6.6 months ±1.3 (95% CI: 4.1--9)\] than patients with low or no ERCC1 production \[median PFS: 10.2 months, mean PFS ± SE: 15.7 months ±4.8 (95% CI: 6.3--25.2)\] (*p* = 0.027). PFS, Progression Free Survival

Moreover, patients without any CD8 TILs expression in their tumors had a more favorable OS profile than patients with tumors expressing CD8 at any grade (mOS: 13.5 vs 8.6 months respectively, *p* = 0.041) (Table [4](#Tab4){ref-type="table"}). Patients with higher levels of COX2 expression tended to had shorter OS than patients with low or no COX2 production (mOS: 10.5 vs 17.7 months respectively, *p* = 0.051).

Genotypic polymorphisms and their associations with response and survival outcomes and relevant protein expression {#Sec13}
------------------------------------------------------------------------------------------------------------------

No significant correlations were observed between the response rates and the tested polymorphisms: *MDR1* C3435T (*p* = 0.867), *MDR1* G2677 T (*p* = 0.191), *ERCC1* C8092A (*p* = 0.454), *ERCC1* N118 N (*p* = 0.479).

Interestingly, the presence of E*RCC1* N118 N polymorphism seemed to translate in ERCC1 protein expression, since all the tumors with the CT genotype were stained positive for ERCC1 protein \[20/20 (100%)\]. This was not the case for the other two genotypes \[CC: 4/6 (66.6%), TT: 12/17 (70.6%)\] (*p* = 0.013) or *ERCC1* C8092A polymorphisms that did not show to affect ERCC1 protein levels (*p* = 0.358).

On the contrary, *MDR1* G2677 T and *ERCC1* N118 N genetic polymorphisms examined in the study appeared to influence the median PFS of patients with metastatic or recurrent cervical cancer. Patients with GT in the site of the *MDR1* G2677 T polymorphism demonstrated longer intervals without disease progression (mPFS: 8.6 months) than patients with GG at the same site (mPFS: 5.1 months), who in turn had longer PFS than patients with TT at the same site (mPFS: 2.9 months, *p* = 0.027) (Fig. [3](#Fig3){ref-type="fig"}). In addition, patients with TT in the site of the *ERCC1* N118 N polymorphism lived longer without disease progression (mPFS: 8.8 months) than patients with CC at the same site (mPFS: 5.2 months) and patients with CT at the same site (mPFS: 3.9 months, *p* = 0.006) (Fig. [4](#Fig4){ref-type="fig"}). Finally, PFS was not affected significantly by the genetic polymorphisms *MDR1* C3435T (*p* = 0.654) or *ERCC1* C8092A (*p* = 0.543). Moreover, the *ERCC1* N118 N polymorphism still was a strong predictor of disease progression (*p* = 0.007) after multivariate analysis.Fig. 3PFS according to *MDR1* G2677 T polymorphism. Patients with GT in the site of the *MDR1* G2677 T polymorphism lived longer without disease progression \[median PFS: 8.6 months, mean PFS ± SE: 16.2 months ±5 (95% CI: 6.3--26)\] than patients with GG at the same site \[median PFS: 5.1 months, mean PFS ± SE: 7.2 ± 1.5 (95% CI: 4.2--10.20)\], who in turn had longer progression-free survival than patients with TT at the same site \[median PFS: 2.9 months, mean PFS ± SE: 4 months ±1.3 (95% CI: 1.4--6.6)\] (*p* = 0.027). PFS, Progression Free Survival Fig. 4PFS according to *ERCC1* N118 N polymorphism. Patients with TT in the site of the *ERCC1* N118 N polymorphism lived longer without disease progression \[median PFS: 8.8 months, mean PFS ± SE: 14.5 months ±3.6 (95% CI: 7.5--21.5)\] than patients with CC at the same site \[median PFS: 5.2 months, mean PFS ± SE: 5.9 ± 1.3 (95% CI: 3.4--8.4)\] and patients with CT at the same site \[median PFS: 3.9 months, mean PFS ± SE: 5.1 months ±1 (95% CI: 3--7.1)\] (*p* = 0.006). PFS, Progression Free Survival

Discussion {#Sec14}
==========

Metastatic or recurrent cancer of the uterine cervix remains a major cause of death for women. These patients are mainly treated with palliative chemotherapy and their prognosis remains extremely poor. Therefore, recognizing resistance or susceptibility to the current standard cisplatin and paclitaxel based treatment may improve patient outcomes and direct selected patients to other new possible options such as immunotherapy or targeted agents. Back in 2000, Britten et al. described a statistically significant (*p* \< 0.011) association between high ERCC1 mRNA levels and cisplatin resistance in human cervical cancer cell lines. Thereafter, several studies tested ERCC1 as a possible marker of resistance in cervical cancer \[[@CR31]\]. High ERCC1 expression was a poor prognostic factor and was correlated with poor disease-free survival (DFS) (*p* = 0.021) and OS (*p* = 0.005) in 88 locally advanced cervical cancer (LACC) patients who received cisplatin monotherapy as reported by Zwenger et al. \[[@CR32]\]. Similarly, class III-β tubulin did not demonstrate a significant association with response, nor prognosis in a series of 98 LACC patients subjected to concurrent chemoradiotherapy \[[@CR33]\]. Accordingly, in a larger Canadian study including 264 LACC patients undergoing curative chemoradiation, ERCC1 expression was positively correlated with PFS (HR 2.33 \[1.05--5.18\], *P* = .038) and OS (HR 3.13 \[1.27--7.71\], *P* = .013), but was not an independent prognostic factor \[[@CR34]\]. Interestingly enough, the same group showed that ERCC1 expression was significantly correlated with both OS (*p* = 0.002) and DFS (*p* = 0.010) among 186 patients undergoing radical radiotherapy alone \[[@CR35]\]. Worse DFS was also documented among 25 patients with FIGO IB -- IIB cervical cancer who underwent either concurrent chemoradiotherapy with cisplatin or cisplatin-based chemotherapy and demonstrated high ERCC1 protein expression (*P* = 0.002) \[[@CR36]\]. Similar results have been reported also in the neoadjuvant setting among 43 stage IIB patients receiving etoposide and cisplatin. Park et al. showed that ERCC1 remained an independent negative predictive factor for response (*p* = 0.021) to cisplatin containing treatment \[[@CR37]\]. Contradictory results have been also published by Muallem et al. in 112 LACC patients treated with cisplatin-based chemo-radiotherapy showing that high levels of ERCC1 expression correlated with favorable outcomes of patients \[[@CR38]\].

To our knowledge, there has not been so far a description of the common *ERCC1* and *MDR1* gene SNPs associated with chemotherapy resistance and survival in recurrent or metastatic cervical cancer, nor its correlation with ERCC1 protein expression. Moreover, in the present study the chemotherapy backbone was cisplatin but also half of the patients were treated with paclitaxel, giving us the opportunity to explore resistance and outcome patterns to taxane chemotherapy. Indeed, the addition of paclitaxel (ITP regimen) did improve patient outcomes as described previously \[[@CR25]\], and high III β-tubulin expression was associated with chemotherapy resistance, as it was linked with lower responses \[5/20 (25%)\] compared to lower expression of ΙΙΙ β-tubulin \[15/23 (65.2%)\] (*p* = 0.008). Although we recognize that the number of patients in our cohort are rather small, the multivariate analysis performed did show that the type of treatment, that is the addition of paclitaxel in ITP regimen (Ifosphamide, Paclitaxel, cisplatin) to IP ((Ifosphamide, cisplatin) did not confound the results, since high expression of III β-tubulin remained an independent predictor of response to treatment. If our results are confirmed in larger cohorts, testing III β-tubulin expression could provide a predictive tool for response to treatment and possibly guide those patients to enroll in clinical trials testing alternative treatment options

Surprisingly, ERCC1 protein expression and the examined *ERCC1* polymorphisms could not predict resistance to cisplatin based chemotherapy in this small metastatic or recurrent cervical cancer cohort. This may in part be due to the 8F1 antibody used for staining ERCC1. Recent data from the NSCLC setting suggest that this antibody cannot differentiate between the 4 isoforms of ERCC1 and more specifically the isoform 202 that is related to platinum sensitivity \[[@CR39]\]. Another explanation would be that the results were underpowered due to the small number of patients in the study.

However, similarly to the studies in LACC, ERCC1 expression proved to be a significant prognostic factor for survival in our studied population. Patients with higher levels of ERCC1 had statistically shorter PFS and OS than patients with low ERCC1 expression (mPFS:5.1 vs 10.2 months, *p* = 0.027; mOS: 10.5 vs. 21.4 months, *p* = 0.006). In addition, the genetic polymorphisms *ERCC1* N118 N and *MDR1* G2677 T appear also to influence the PFS. Patients with TT in the site of the *ERCC1* N118 N polymorphism lived longer without disease progression than patients with CC or CT at the same site \[(median PFS: 8.8, 5.2 and 3.9 months respectively, *p* = 0.006). Furthermore, patients with GT in the site of the *MDR1* G2677 T polymorphism lived longer without disease progression than patients with GG and patients with TT at the same site (median PFS: 8.6 months, 5.1 and 2.9 months respectively, *p* = 0.027). ERCC1 expression and the *ERCC1* N118 N polymorphism remained independent predictors of the PFS after the performed multivariate survival analysis, thus rendering them significant prognostic factors in this metastatic or recurrent cervical cancer population.

Finally, the absence of CD8 expression was also correlated with improved survival in our metastatic cervical cancer cohort. Although this merits further investigation, it is in concordance with the observation that it is the high CD4/CD8 ratio of tumor-infiltrating lymphocytes (TILs) and thus a low CD8 count, that is linked to improved survival of patients with cervical cancer \[[@CR24]\]. Furthermore, in the later study, better clinical outcomes were shown when a high percentage of CD4 TILs combined with a low percentage of FOX 3 CD4 regulatory T cells was present \[[@CR24]\].

Conclusions {#Sec15}
===========

In conclusion, our data should be interpreted with caution given the small numbers of the cohort. However, these are in major concordance with previous data underlying the prognostic role of ERCC1 expression and its polymorphisms in the outcome of patients treated with platinum cytotoxic damaging agents. Furthermore, the efficacy of the already included paclitaxel in the standard treatment of metastatic cervical cancer may possibly be influenced by III β-tubulin expression and the described *MDR1* polymorphisms. In the new era of targeted therapies, the above information could be used to recognize specific subgroups of patients that would derive the major benefit from chemotherapy and those with poor prognosis that should be directed to clinical trials with novel promising agents.

COX-2
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:   Multiple Drug Resistance
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